Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Kevin M Tuffy"'
Autor:
Bahar Ahani, Kevin M. Tuffy, Anastasia A. Aksyuk, Deidre Wilkins, Michael E. Abram, Ron Dagan, Joseph B. Domachowske, Johnathan D. Guest, Hong Ji, Anna Kushnir, Amanda Leach, Shabir A. Madhi, Vaishali S. Mankad, Eric A. F. Simões, Benjamin Sparklin, Scott D. Speer, Ann Marie Stanley, David E. Tabor, Ulrika Wählby Hamrén, Elizabeth J. Kelly, Tonya Villafana
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-2 (2024)
Externí odkaz:
https://doaj.org/article/62972434e0cc4edfafbaf60c3024f8ec
Autor:
Lindsay E Clegg, Oleg Stepanov, Sam Matthews, Tom White, Seth Seegobin, Steven Thomas, Kevin M Tuffy, Mats Någård, Mark T Esser, Katie Streicher, Taylor S Cohen, Anastasia A Aksyuk
Publikováno v:
Clinical & Translational Immunology, Vol 13, Iss 6, Pp n/a-n/a (2024)
Abstract Objectives The evolution of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) necessitates rapid methods for assessing monoclonal antibody (mAb) potency against emerging variants. Authentic virus neutralisation assays are cons
Externí odkaz:
https://doaj.org/article/d383527f067748c0a99eb961c96ff5ba
Autor:
Bahar Ahani, Kevin M. Tuffy, Anastasia A. Aksyuk, Deidre Wilkins, Michael E. Abram, Ron Dagan, Joseph B. Domachowske, Johnathan D. Guest, Hong Ji, Anna Kushnir, Amanda Leach, Shabir A. Madhi, Vaishali S. Mankad, Eric A. F. Simões, Benjamin Sparklin, Scott D. Speer, Ann Marie Stanley, David E. Tabor, Ulrika Wählby Hamrén, Elizabeth J. Kelly, Tonya Villafana
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-10 (2023)
Abstract Nirsevimab is a monoclonal antibody that binds to the respiratory syncytial virus (RSV) fusion protein. During the Phase 2b (NCT02878330) and MELODY (NCT03979313) clinical trials, infants received one dose of nirsevimab or placebo before the
Externí odkaz:
https://doaj.org/article/fb9efa8bfa3c458ebbb25e11a772eeb6
Autor:
Tyler Brady, Corinne Cayatte, Tiffany L. Roe, Scott D. Speer, Hong Ji, LeeAnn Machiesky, Tianhui Zhang, Deidre Wilkins, Kevin M. Tuffy, Elizabeth J. Kelly
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionNirsevimab is an extended half-life (M252Y/S254T/T256E [YTE]-modified) monoclonal antibody to the pre-fusion conformation of the respiratory syncytial virus (RSV) Fusion protein, with established efficacy in preventing RSV-associated lowe
Externí odkaz:
https://doaj.org/article/c72eec9d7aad4feda1ae2f5d53e8d316
Autor:
Tyler Brady, Tianhui Zhang, Kevin M. Tuffy, Nantaporn Haskins, Qun Du, Jia Lin, Gilad Kaplan, Steven Novick, Tiffany L. Roe, Kuishu Ren, Kim Rosenthal, Patrick M. McTamney, Michael E. Abram, Katie Streicher, Elizabeth J. Kelly
Publikováno v:
Microbiology Spectrum, Vol 10, Iss 5 (2022)
ABSTRACT AZD7442, a combination of two long-acting monoclonal antibodies (tixagevimab [AZD8895] and cilgavimab [AZD1061]), has been authorized for the prevention and treatment of coronavirus disease 2019 (COVID-19). The rapid emergence of severe acut
Externí odkaz:
https://doaj.org/article/98d4176648a242c59e666ffdfbd7fce6
Autor:
Deidre Wilkins, Anastasia A Aksyuk, Alexey Ruzin, Kevin M Tuffy, Tina Green, Rebecca Greway, Brittany Fikes, Cyrille J Bonhomme, Mark T Esser, Elizabeth J Kelly
Publikováno v:
Clinical & Translational Immunology, Vol 11, Iss 4, Pp n/a-n/a (2022)
Abstract Objectives Robust, quantitative serology assays are required to accurately measure antibody levels following vaccination and natural infection. We present validation of a quantitative, multiplex, SARS‐CoV‐2, electrochemiluminescent (ECL)
Externí odkaz:
https://doaj.org/article/185998943a9c4bd88730c7fd662763ef
Autor:
Rebecca J. Kaddis Maldonado, Breanna Rice, Eunice C. Chen, Kevin M. Tuffy, Estelle F. Chiari, Kelly M. Fahrbach, Thomas J. Hope, Leslie J. Parent
Publikováno v:
mBio, Vol 11, Iss 2 (2020)
ABSTRACT Packaging of genomic RNA (gRNA) by retroviruses is essential for infectivity, yet the subcellular site of the initial interaction between the Gag polyprotein and gRNA remains poorly defined. Because retroviral particles are released from the
Externí odkaz:
https://doaj.org/article/bf766209481249ad8367d0ebaef4f5cb
Autor:
Tiffany L. Roe, Tyler Brady, Nicolette Schuko, Amy Nguyen, Jagadish Beloor, Johnathan D. Guest, Anastasia A. Aksyuk, Kevin M. Tuffy, Tianhui Zhang, Katie Streicher, Elizabeth J. Kelly, Gustavo H. Kijak
Publikováno v:
Microbiology Spectrum. 11
MAbs are key therapeutic options for COVID-19 prophylaxis and treatment in immunosuppressed and vulnerable populations. Due to the emergence of SARS-CoV-2 variants, including Omicron, it is vital to ensure that neutralization is maintained for MAb-ba
Autor:
Kevin M Tuffy, Michael E Abram, Tiffany L Roe, Bahar Ahani, Tyler Brady, Nicolette Schuko, Lori Clarke, Carolina Caceres, Tara Kenny, Virginia Takahashi, Tianhui Zhang, David E Tabor, Gustavo H Kijak, Elizabeth J Kelly, Katie Streicher
Publikováno v:
Open Forum Infectious Diseases. 9
Background AZD7442 is a combination of extended–half-life SARS-CoV-2–neutralizing monoclonal antibodies (tixagevimab/cilgavimab) that bind to distinct epitopes on the SARS-CoV-2 spike protein. In the PROVENT study, a single 300 mg intramuscular d
Autor:
Michael E Abram, Bahar Ahani, David E Tabor, Fiona Fernandes, Deidre Wilkins, Anastasia A Aksyuk, Kevin M Tuffy, Hong Ji, Christine Blaze, Tyler Brady, Pamela Griffin, Amanda Leach, Tonya L Villafana, Mark T Esser
Publikováno v:
Open Forum Infectious Diseases. 9
Background Respiratory syncytial virus (RSV) is the major cause of lower respiratory tract infection (LRTI) and hospitalization in infants. In two global pivotal placebo-controlled studies, nirsevimab, a monoclonal antibody to the RSV prefusion (F) p